Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

APOE2 orchestrated differences in transcriptomic and lipidomic profiles of postmortem AD brain.

Lefterov I, Wolfe CM, Fitz NF, Nam KN, Letronne F, Biedrzycki RJ, Kofler J, Han X, Wang J, Schug J, Koldamova R.

Alzheimers Res Ther. 2019 Dec 30;11(1):113. doi: 10.1186/s13195-019-0558-0.

2.

Therapeutic targeting of nuclear receptors, liver X and retinoid X receptors, for Alzheimer's disease.

Fitz NF, Nam KN, Koldamova R, Lefterov I.

Br J Pharmacol. 2019 Sep;176(18):3599-3610. doi: 10.1111/bph.14668. Epub 2019 May 11. Review.

PMID:
30924124
3.

The Role of APOE and TREM2 in Alzheimer's Disease-Current Understanding and Perspectives.

Wolfe CM, Fitz NF, Nam KN, Lefterov I, Koldamova R.

Int J Mol Sci. 2018 Dec 26;20(1). pii: E81. doi: 10.3390/ijms20010081. Review.

4.

ABCA1 haplodeficiency affects the brain transcriptome following traumatic brain injury in mice expressing human APOE isoforms.

Castranio EL, Wolfe CM, Nam KN, Letronne F, Fitz NF, Lefterov I, Koldamova R.

Acta Neuropathol Commun. 2018 Jul 26;6(1):69. doi: 10.1186/s40478-018-0569-2.

5.

Integrated approach reveals diet, APOE genotype and sex affect immune response in APP mice.

Nam KN, Wolfe CM, Fitz NF, Letronne F, Castranio EL, Mounier A, Schug J, Lefterov I, Koldamova R.

Biochim Biophys Acta Mol Basis Dis. 2018 Jan;1864(1):152-161. doi: 10.1016/j.bbadis.2017.10.018. Epub 2017 Oct 14.

6.

Effect of high fat diet on phenotype, brain transcriptome and lipidome in Alzheimer's model mice.

Nam KN, Mounier A, Wolfe CM, Fitz NF, Carter AY, Castranio EL, Kamboh HI, Reeves VL, Wang J, Han X, Schug J, Lefterov I, Koldamova R.

Sci Rep. 2017 Jun 27;7(1):4307. doi: 10.1038/s41598-017-04412-2.

7.

Gene co-expression networks identify Trem2 and Tyrobp as major hubs in human APOE expressing mice following traumatic brain injury.

Castranio EL, Mounier A, Wolfe CM, Nam KN, Fitz NF, Letronne F, Schug J, Koldamova R, Lefterov I.

Neurobiol Dis. 2017 Sep;105:1-14. doi: 10.1016/j.nbd.2017.05.006. Epub 2017 May 11.

8.

Liver X receptor agonist treatment significantly affects phenotype and transcriptome of APOE3 and APOE4 Abca1 haplo-deficient mice.

Carter AY, Letronne F, Fitz NF, Mounier A, Wolfe CM, Nam KN, Reeves VL, Kamboh H, Lefterov I, Koldamova R.

PLoS One. 2017 Feb 27;12(2):e0172161. doi: 10.1371/journal.pone.0172161. eCollection 2017.

9.

ABCA1 Deficiency Affects Basal Cognitive Deficits and Dendritic Density in Mice.

Fitz NF, Carter AY, Tapias V, Castranio EL, Kodali R, Lefterov I, Koldamova R.

J Alzheimers Dis. 2017;56(3):1075-1085. doi: 10.3233/JAD-161056.

10.

Apolipoprotein E*4 (APOE*4) Genotype Is Associated with Altered Levels of Glutamate Signaling Proteins and Synaptic Coexpression Networks in the Prefrontal Cortex in Mild to Moderate Alzheimer Disease.

Sweet RA, MacDonald ML, Kirkwood CM, Ding Y, Schempf T, Jones-Laughner J, Kofler J, Ikonomovic MD, Lopez OL, Garver ME, Fitz NF, Koldamova R, Yates NA.

Mol Cell Proteomics. 2016 Jul;15(7):2252-62. doi: 10.1074/mcp.M115.056580. Epub 2016 Apr 21.

11.

RXR controlled regulatory networks identified in mouse brain counteract deleterious effects of Aβ oligomers.

Nam KN, Mounier A, Fitz NF, Wolfe C, Schug J, Lefterov I, Koldamova R.

Sci Rep. 2016 Apr 7;6:24048. doi: 10.1038/srep24048.

12.

Opposing effects of Apoe/Apoa1 double deletion on amyloid-β pathology and cognitive performance in APP mice.

Fitz NF, Tapias V, Cronican AA, Castranio EL, Saleem M, Carter AY, Lefterova M, Lefterov I, Koldamova R.

Brain. 2015 Dec;138(Pt 12):3699-715. doi: 10.1093/brain/awv293. Epub 2015 Oct 28.

13.

Bexarotene-Activated Retinoid X Receptors Regulate Neuronal Differentiation and Dendritic Complexity.

Mounier A, Georgiev D, Nam KN, Fitz NF, Castranio EL, Wolfe CM, Cronican AA, Schug J, Lefterov I, Koldamova R.

J Neurosci. 2015 Aug 26;35(34):11862-76. doi: 10.1523/JNEUROSCI.1001-15.2015.

14.

RNA-sequencing reveals transcriptional up-regulation of Trem2 in response to bexarotene treatment.

Lefterov I, Schug J, Mounier A, Nam KN, Fitz NF, Koldamova R.

Neurobiol Dis. 2015 Oct;82:132-140. doi: 10.1016/j.nbd.2015.05.019. Epub 2015 Jun 10.

15.

Metabolic Disorders and Neurodegeneration, introduction to the special issue.

Lefterov I, Koldamova R.

Neurobiol Dis. 2014 Dec;72 Pt A:1-2. No abstract available.

PMID:
25301714
16.

ATP-binding cassette transporter A1: from metabolism to neurodegeneration.

Koldamova R, Fitz NF, Lefterov I.

Neurobiol Dis. 2014 Dec;72 Pt A:13-21. doi: 10.1016/j.nbd.2014.05.007. Epub 2014 May 17. Review.

17.

Improvement of memory deficits and amyloid-β clearance in aged APP23 mice treated with a combination of anti-amyloid-β antibody and LXR agonist.

Fitz NF, Castranio EL, Carter AY, Kodali R, Lefterov I, Koldamova R.

J Alzheimers Dis. 2014;41(2):535-49. doi: 10.3233/JAD-132789.

18.

Genome-wide approaches reveal EGR1-controlled regulatory networks associated with neurodegeneration.

Koldamova R, Schug J, Lefterova M, Cronican AA, Fitz NF, Davenport FA, Carter A, Castranio EL, Lefterov I.

Neurobiol Dis. 2014 Mar;63:107-14. doi: 10.1016/j.nbd.2013.11.005. Epub 2013 Nov 20.

19.

Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

Fitz NF, Cronican AA, Lefterov I, Koldamova R.

Science. 2013 May 24;340(6135):924-c. doi: 10.1126/science.1235809.

20.

Genome-wide alteration of histone H3K9 acetylation pattern in mouse offspring prenatally exposed to arsenic.

Cronican AA, Fitz NF, Carter A, Saleem M, Shiva S, Barchowsky A, Koldamova R, Schug J, Lefterov I.

PLoS One. 2013;8(2):e53478. doi: 10.1371/journal.pone.0053478. Epub 2013 Feb 6.

21.

Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice.

Fitz NF, Cronican AA, Saleem M, Fauq AH, Chapman R, Lefterov I, Koldamova R.

J Neurosci. 2012 Sep 19;32(38):13125-36.

22.

Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 mice.

Lefterov I, Fitz NF, Cronican AA, Fogg A, Lefterov P, Kodali R, Wetzel R, Koldamova R.

J Biol Chem. 2010 Nov 19;285(47):36945-57. doi: 10.1074/jbc.M110.127738. Epub 2010 Aug 25.

23.

Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice.

Fitz NF, Cronican A, Pham T, Fogg A, Fauq AH, Chapman R, Lefterov I, Koldamova R.

J Neurosci. 2010 May 19;30(20):6862-72. doi: 10.1523/JNEUROSCI.1051-10.2010.

24.

The role of ATP-binding cassette transporter A1 in Alzheimer's disease and neurodegeneration.

Koldamova R, Fitz NF, Lefterov I.

Biochim Biophys Acta. 2010 Aug;1801(8):824-30. doi: 10.1016/j.bbalip.2010.02.010. Epub 2010 Feb 24. Review.

25.

Anti-Amyloid Effects of Small Molecule Aβ-Binding Agents in PS1/APP Mice.

Cohen AD, Ikonomovic MD, Abrahamson EE, Paljug WR, Dekosky ST, Lefterov IM, Koldamova RP, Shao L, Debnath ML, Mason NS, Mathis CA, Klunk WE.

Lett Drug Des Discov. 2009 Sep;6(6):437.

26.

Proton pump inhibitor lansoprazole is a nuclear liver X receptor agonist.

Cronican AA, Fitz NF, Pham T, Fogg A, Kifer B, Koldamova R, Lefterov I.

Biochem Pharmacol. 2010 May 1;79(9):1310-6. doi: 10.1016/j.bcp.2009.12.018. Epub 2010 Jan 8.

27.

Memory deficits in APP23/Abca1+/- mice correlate with the level of Aβ oligomers.

Lefterov I, Fitz NF, Cronican A, Lefterov P, Staufenbiel M, Koldamova R.

ASN Neuro. 2009 Apr 30;1(2). pii: e00006. doi: 10.1042/AN20090015.

28.

Expression profiling in APP23 mouse brain: inhibition of Abeta amyloidosis and inflammation in response to LXR agonist treatment.

Lefterov I, Bookout A, Wang Z, Staufenbiel M, Mangelsdorf D, Koldamova R.

Mol Neurodegener. 2007 Oct 22;2:20.

29.

Role of LXR and ABCA1 in the pathogenesis of Alzheimer's disease - implications for a new therapeutic approach.

Koldamova R, Lefterov I.

Curr Alzheimer Res. 2007 Apr;4(2):171-8. Review.

PMID:
17430243
30.

Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.

Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, Debnath ML, Holt DP, Huang GF, Shao L, DeKosky ST, Price JC, Mathis CA.

J Neurosci. 2005 Nov 16;25(46):10598-606.

31.

Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice.

Koldamova R, Staufenbiel M, Lefterov I.

J Biol Chem. 2005 Dec 30;280(52):43224-35. Epub 2005 Oct 5.

32.

The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease.

Koldamova RP, Lefterov IM, Staufenbiel M, Wolfe D, Huang S, Glorioso JC, Walter M, Roth MG, Lazo JS.

J Biol Chem. 2005 Feb 11;280(6):4079-88. Epub 2004 Nov 22.

33.

Sleuthful pharmacology.

Lazo JS, Ducruet AP, Koldamova RP.

Mol Pharmacol. 2003 Aug;64(2):199-201. No abstract available.

PMID:
12869623
34.

22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion.

Koldamova RP, Lefterov IM, Ikonomovic MD, Skoko J, Lefterov PI, Isanski BA, DeKosky ST, Lazo JS.

J Biol Chem. 2003 Apr 11;278(15):13244-56. Epub 2003 Jan 22.

35.

Spin-labeled 1-alkyl-1-nitrosourea synergists of antitumor antibiotics.

Gadjeva V, Koldamova R.

Anticancer Drug Des. 2001 Aug-Oct;16(4-5):247-53.

PMID:
12049483
36.

Cysteine 73 in bleomycin hydrolase is critical for amyloid precursor protein processing.

Lefterov IM, Koldamova RP, Lefterova MI, Schwartz DR, Lazo JS.

Biochem Biophys Res Commun. 2001 May 18;283(4):994-9.

PMID:
11350084
37.

Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity.

Koldamova RP, Lefterov IM, Lefterova MI, Lazo JS.

Biochemistry. 2001 Mar 27;40(12):3553-60.

PMID:
11297421
38.

Human bleomycin hydrolase regulates the secretion of amyloid precursor protein.

Lefterov IM, Koldamova RP, Lazo JS.

FASEB J. 2000 Sep;14(12):1837-47.

PMID:
10973933
39.

Human bleomycin hydrolase binds ribosomal proteins.

Koldamova RP, Lefterov IM, DiSabella MT, Almonte C, Watkins SC, Lazo JS.

Biochemistry. 1999 Jun 1;38(22):7111-7.

PMID:
10353821
40.
41.

The C-terminus of human bleomycin hydrolase is required for protection against bleomycin-induced chromosomal damage.

Lefterov IM, Koldamova RP, King J, Lazo JS.

Mutat Res. 1998 Oct 12;421(1):1-7.

PMID:
9748474
42.

Essential binding and functional domains of human bleomycin hydrolase.

Koldamova RP, Lefterov IM, Gadjeva VG, Lazo JS.

Biochemistry. 1998 Feb 24;37(8):2282-90.

PMID:
9485374
43.
44.

Supplemental Content

Loading ...
Support Center